Sail Biomedicines

While many are familiar with the incredible therapeutic potential of RNA medicines, beyond a handful of approved products, the true promise of these therapies has not yet been realized, leaving patient needs unmet.

Sail Biomedicines is developing a unique, next-generation RNA medicines platform designed to solve some of the greatest challenges associated with conventional mRNA therapeutics, unlocking programmable medicines and potentially leading to better options for patients, faster.

Sail works at the frontier of programmable medicines, powering its bioplatform and product candidates by harnessing evolution and AI.  It operates with purpose and urgency on behalf of people everywhere, with the aim to generate life-changing impact for the world.

By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of proprietary AI algorithms for the integrative design of RNA medicines.

Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse therapeutic proteins inside the body.  It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.

In October 2023, Flagship Pioneering announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the design and deployment of fully programmable medicines to transform patient care. Senda’s platform was the first to leverage a universal chemical code of natural nanoparticles that enables directed and repeatable deployment of payloads, such as translatable RNA, directly to cells and tissues of choice.  Laronde pioneered eRNA, a new class of synthetic, translatable RNA that can be programmed to express diverse proteins inside the body, with vast therapeutic potential.

The JIMCO Life Sciences Fund participated in Laronde’s Series B funding round in August 2021 to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories.